The Pfizer/BioNTech group announced on Friday 30 April that it had submitted an application to the European Medicines Agency (EMA) to extend the authorisation of its Covid-19 vaccine so that it could be administered to young people aged 12 to 15 years.
The two companies explained in a statement that the request is based on data from a pivotal phase 3 clinical trial that involved 2,260 participants aged 12–15 years.
“Topline results from this trial, announced on March 31, 2021, showed a...